Key Proteo is a Seattle-based proteomics diagnostics company founded in 2019 that develops early detection of rare but treatable genetic disorders, starting with newborn screening. Its patent-pending Immuno-SRM platform quantifies extremely low-abundance protein biomarkers from a few drops of blood, with faster turnaround and lower cost than next-generation sequencing. Its first panel targets four disorders including Wilson disease and Wiskott-Aldrich syndrome; the company earned CLIA certification in 2025 and Wilson disease screening was added to the Washington State newborn screening program that year.
1
Round
1
Industry
5
Tags
Oct 23, 2026
Latest raise
Funding activity · 1 round
Oct 23, 2026
$2.3M
Series A
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
